Illumina (ILMN) is back in focus after a period of strong share-price swings, with the stock up about 12% over the past month and roughly 29% in the past 3 months.

Zooming out, Illumina’s 12.1% 1 month share price return and 28.5% 3 month share price return sit alongside a 78.7% 1 year total shareholder return. However, 3 and 5 year total shareholder returns remain negative, suggesting recent momentum contrasts with a weaker longer term record.

If you are looking for other healthcare and genomics related opportunities, this is a good moment to scan the market using our screener for 38 healthcare AI stocks

With Illumina stock recently rebounding and trading at an intrinsic discount estimate of about 33%, the key question now is whether this pricing still reflects value or if the market is already baking in ambitious growth expectations.

Most Popular Narrative: 10% Overvalued

Illumina's most followed narrative points to a fair value of about $147 per share, which sits below the recent close around $162, and frames current pricing as slightly ahead of consensus expectations.

Strong and resilient growth in clinical applications, especially oncology, genetic disease testing, and reproductive health, continues to expand as genomic technologies become the standard of care, supporting both recurring revenues from consumables and long-term earnings visibility.

Increasing adoption of next-generation sequencing for preventive healthcare and early disease detection is driving broader utilization of Illumina's platforms, particularly as clinical markets now represent over 60% of sequencing consumables, positioning the business for sustained volume and revenue growth.

Curious what growth path and margin profile have to line up for Illumina to justify that fair value tag? The narrative leans on steady revenue expansion, firmer profitability, and a future earnings multiple that has to compress from today, yet still stay above more conservative benchmarks. The numbers behind that storyline might surprise you.

Result: Fair Value of $147 (OVERVALUED)

However, Illumina’s story still carries pressure points, particularly ongoing research funding constraints and regulatory uncertainty in China. These factors could unsettle revenue expectations and margin assumptions.

Another View: Illumina Through The SWS DCF Lens

While the most followed Illumina narrative frames the stock as about 10% overvalued versus a $147 fair value, the SWS DCF model presents a different picture. It shows an estimated future cash flow value of $239.90 per share, which implies that the current $161.93 price sits well below that level. Which yardstick do you find more convincing when the signals disagree?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Illumina for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Seeing both bullish and cautious signals around Illumina in the same place can be unsettling, so move quickly to test the assumptions, compare upside and downside, and then weigh the 3 key rewards and 2 important warning signs.

Looking for more ideas beyond Illumina?

If Illumina has your attention, do not stop there. Cast a wider net now and give yourself more options before the next wave of opportunities moves on.

• Target resilient balance sheets by scanning companies in the solid balance sheet and fundamentals stocks screener (48 results) that combine financial strength with room for future decisions.
• Hunt for potential mispricings using the 45 high quality undervalued stocks to spot businesses where current prices sit below underlying fundamentals.
• Prioritise lower volatility by reviewing companies in the 66 resilient stocks with low risk scores that score well on risk and financial stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.